PATENT CLAIM ANALYSIS

Application Number: 15877436
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["424", "133100"]

Abstract:
The present invention relates to a pharmaceutical composition comprising PD-1 antagonist and an EGFR Inhibitor. The present combination can be administered independently or separately, in a quantity which is jointly therapeutically effective for the treatment of cancer. The invention also provides the use of such a combination for the manufacture of a medicament; the use of such a combination as a medicine; a kit of part comprising such a combination; and a method of treatment of such a combination.

Claim (Index 54):
The pharmaceutical combination for use according to  claim 41 , wherein Compound A is administered at a dose of between 5 mg and 100 mg, e.g., at a dose of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 75 mg, or 100 mg.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 86.0
- Lexical Diversity: 1.79167
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14604415', '15751140', '14881888', '15595618', '14610837']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7595533302090209
- 35 USC 102 Novelty (BERT): 0.5303697028638429
- Combined Prediction Score: 0.7366349674745032
- Mean Citation Score: 334.040494
- Max Citation Score: 353.73898
- Similarity Product: 243.7551099304855

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test